drugset / Trial / NCT01774968

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968

Phase 4 Completed 325 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.

Timeline

Start
2013-02
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Subcutaneous